INTRODUCTION {#s1}
============

Urothelial bladder cancer (UBC) is the fifth most common cancer worldwide \[[@R1]\] and is one of the most management intensive cancers in North America \[[@R2]\]. Although the majority of incident cases of UBC are non-invasive at presentation, muscle invasive bladder cancer (MIBC) represents very aggressive disease with rapid progression to metastases \[[@R3]\] and poor overall survival despite intensive local and systemic therapy. Current standards for localized MIBC include radical cystectomy with or without perioperative cisplatin-based chemotherapy \[[@R3]\]. Unfortunately, many suffer early disease recurrence and, despite palliative chemotherapy, median survival rates are generally less than one year \[[@R4]\]. The optimal management of patients with higher risk UBC is ambiguous with a significant need for better prediction tools and enhanced therapeutics \[[@R5]\].

MIBCs are highly heterogeneous tumours. Recent investigations based on molecular profiling of specimens from large UBC cohorts have led to their classification into molecular subtypes that display distinct genomic and transcriptomic features, resembling those seen in breast cancer \[[@R3]\], \[[@R6]--[@R8]\]. Interestingly, these subtypes may exhibit distinct associations with treatment response and survival \[[@R8], [@R9]\]. Although different groups have classified UBC into two \[[@R8]\], three \[[@R3]\], four \[[@R6]\], or five \[[@R7]\] subtypes, there is a consensus that the top separation occurs as the basal and luminal subtypes \[[@R10]\]. Basal tumours, enriched with EGFR and hypoxia-inducible factor 1 expression, are often metastatic at presentation, possess squamous and sarcomatoid histological features, and have epithelial-to-mesenchymal transition cell biomarkers \[[@R11]\]. In comparison, luminal cancers have papillary features and commonly *FGFR3*, *ERBB2*, and *ERBB3* activating mutations \[[@R11]\]. The Cancer Genome Atlas Network (TCGA) bladder analysis working group classified bladder tumours into four clusters named I, II, III, and IV \[[@R6]\]. Clusters I and II correspond to the luminal subtype, while III and IV represent the basal subtype \[[@R12]\]. Tumours in Cluster I are enriched in *FGFR3* overexpression due to mutations and amplification and show better overall survival, whereas those in cluster II, designated "p53-like" tumours, express active p53 gene signatures and are resistant to neoadjuvant cisplatin-based combination chemotherapy \[[@R3]\]. Cluster IV shares features with the claudin-low subtype of breast cancer, express immune checkpoint molecules, and were actively immunosuppressed, despite having an enriched immune gene signature \[[@R13]\]. In particular, Kardos et al. \[[@R13]\] demonstrated that immune infiltration was not correlated with predicted neoantigen burden, but from unopposed NF-kB activity from downregulated PPARγ signaling.

Given the urgent need of alternative approaches in MIBC treatment, there has been a growing interest in immunotherapies, such as those targeting the immune checkpoints: CTLA-4, PD-L1, and PD-1 \[[@R14]\]. Atezolizumab, a PD-L1 inhibitor, has been recently approved by the FDA for bladder cancer that progressed during or following chemotherapy \[[@R15]\]. Evolving evidence based on the success of immune checkpoint blockade therapies in melanoma and non-small cell lung cancer has confirmed the significance of the pre-treatment tumour immune state as a strong prognostic and response predictive indicator \[[@R14], [@R16]\]. An important feature, key to the success of immunotherapy, is the spatial organization of cytotoxic CD8^+^ tumour infiltrating lymphocytes (TILs) in the epithelial and stromal compartments and their activation status \[[@R17]\]. Higher density of CD3^+^ and CD8^+^ TILs have been associated with increased disease-free and overall survival in melanoma, head and neck, breast, bladder, urothelial, ovarian, colorectal, prostatic, and lung cancer; however, their activation status determines their prognostic significance in most cancers \[[@R18], [@R19]\]. In particular the expression of interferons (IFNs), which play a central role in anti-tumour immune responses, are emerging as prognostic and predictive biomarkers of both chemotherapy and immunotherapy \[[@R20]\]. Higher infiltration with CD4^+^ and regulatory subsets of TILs and higher CD68 to CD3 ratios are associated with poor prognosis in bladder cancer \[[@R21]--[@R23]\]. In particular PD-L1, IDO, FOXP3, TIM3, and LAG3 are expressed in T-cell-inflamed, and β-catenin, PPAR-γ, and FGFR3 in non-T-cell-inflamed urothelial tumours \[[@R17]\]. Although the pre-treatment expression of PD-1/PD-L1 initially showed some predictive value, it has recently failed to perform as a good biomarker in the recent clinical trials due to their transient nature of expression \[[@R23]--[@R25]\].

As reported in other cancers sites, it is likely that the pre-existing tumour immune landscape in UBC could be an additive determinant of response to chemotherapy as well as immune-based therapies leading to more precise prognostication, patient stratification, and informed treatment decisions \[[@R26]\]. To our knowledge there are no previous studies in MIBC that have evaluated the association between immune transcriptomic alterations, specifically those mediated by IFNs and cytotoxic pathway genes, and their potential associations with their distinct molecular sub-populations. In the current study, we performed a comprehensive *in silico* immune transcriptomic profiling of MIBC using the publicly available TCGA global transcriptomic datasets in order to determine whether the known molecular subtypes of MIBC are associated with specific immune gene signatures. The findings from our study may not only provide insights into the association between genomic subtypes and immune activation, but may also open novel opportunities for improving the management of MIBC.

RESULTS {#s2}
=======

We aimed to determine whether the previously defined four TCGA MIBC clusters exhibit differences in their immune gene expression patterns that could be of potential significance in informing treatment decisions for immunotherapies and other combinatorial treatment approaches.

Clinicopathological features of TCGA MIBC cohort {#s2_1}
------------------------------------------------

The TCGA cohort as reported earlier, consisted of chemotherapy-naïve, muscle-invasive, high-grade urothelial tumors (T2-T4a, Nx, Mx) \[[@R6]\]. Inclusion criteria reviewed by five expert genitourinary pathologists involved: tumour nuclei ≥ 60% of total, ≤20% tumour necrosis in the specimen, and variant histology ≤50% \[[@R6]\].

Immune gene expression patterns across MIBC clusters {#s2_2}
----------------------------------------------------

First, the 122 samples previously used to identify the four clusters by TCGA \[[@R6]\] were treated as a discovery group to determine immune gene expression profiles across clusters. A total of 377 genes derived from the NanoString™ panel discriminating among the clusters were identified using a feature selection technique ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The performance of these genes to accurately distinguish the four TCGA clusters was evaluated by clustering of cohort 1 (Figure [1](#F1){ref-type="fig"}). This set of genes was then used to assign samples in the validation set to the four clusters. Similar to cohort 1, the genes were able to distinguish the four clusters in cohort 2 by supervised and unsupervised analysis (Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). Similar unsupervised analysis was done using the top 5% of genes derived from all immune panels (n=157) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) on both cohorts (Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). A recent updated analysis of the current TCGA bladder tumour cohort shows that clusters I-IV remained stable \[[@R28]\], supporting our classification approach in cohorts 1 and 2.

![Distinct immune gene expression levels in cohort 1 (n=122) between the four TCGA bladder cancer subtypes based on the top 20% (377 NanosString panel genes) using the feature selection algorithm. Red indicates high expression, and blue indicates low expression.](oncotarget-08-70982-g001){#F1}

![Cohort 2 (n=225) assigned to clusters based on Euclidian distance to the cluster centroids generated from the cohort 1 (n=122)\
Supervised **(A)** and unsupervised **(B)** analysis based on the samples and 377 NanoString™ panel genes.](oncotarget-08-70982-g002){#F2}

![Unsupervised analysis of both the cohort 1 **(A)** and cohort 2 **(B)** using the top 5% (n=157) genes. Unsupervised grouping shows gradient of under expression in cluster I to overexpression in cluster IV.](oncotarget-08-70982-g003){#F3}

Differential pre-existing expression patterns of interferon associated genes {#s2_3}
----------------------------------------------------------------------------

The four cluster patterns were also noted for the top 20% ranking IFN-γ associated genes upon hierarchical clustering analysis in both training and validation cohorts (Figure [4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}). A gradient of under-expression of IFN-γ associated genes in cluster I to overexpression in cluster IV is observed in both. A similar pattern was also noted in the top 20% ranking IFN-α (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}) and cytotoxic genes (Figure [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). Most importantly, key IFN response genes and downstream T-cell recruiting target chemokine genes*, CXCL9*, *CXCL10*, and *CXCL11*, and their common receptor *CXCR3*, showed increased expression in clusters III and IV. Similarly, others in the list included the key players in IFN response such as *IFITM2, CCL5, IRF4* and others.

![Supervised heat map of top 20% of IFN-γ associated pathway genes in both cohort 1 **(A)** and cohort 2 **(B).**](oncotarget-08-70982-g004){#F4}

![Supervised heat map of top 20% of IFN-α associated pathway genes in both discovery **(A)** and validation **(B)** groups.](oncotarget-08-70982-g005){#F5}

![Supervised heat map of top 20% of cytotoxic associated pathway genes in both cohort 1 **(A)** and cohort 2 **(B).**](oncotarget-08-70982-g006){#F6}

Antigen processing pathways are overrepresented in T-cell inflamed MIBC clusters {#s2_4}
--------------------------------------------------------------------------------

We determined the Gene Ontology functional annotations of the differentially expressed genes that distinguished the four clusters, using both the 377 and 157 genes as input gene lists. Using the overrepresentation statistic in PANTHER, we calculated the probability of highly populated protein classes and gene ontology classes among the two gene lists (Table [2a](#T2a){ref-type="table"} and [2b](#T2b){ref-type="table"}). The most enriched GO biological processes in the 377-gene list were response to IFN-γ, antigen processing and presentation, cytokine mediated signaling, hemopoeisis, cell proliferation and cellular defense response ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}). The top five overrepresented pathways included JAK/STAT signaling pathway, Toll-like receptor signaling pathway, interleukin signalling pathway, and T-cell activation (Figure [7](#F7){ref-type="fig"}). Interestingly, similar analysis using the top ranking 157 genes as input list, revealed only the B-cell activation, T-cell activation, and inflammation mediated by chemokine and cytokine signaling pathways as the only three overrepresented pathways. Response to IFN-γ, hemopoiesis, macrophage activation and cell proliferation were the most overrepresented GO biological processes in the top ranked 157 genes ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}).

###### Custom designed immune gene panel of 924 genes, consisting of IFN-α and IFN-γ pathway genes from GSEA and immune response genes defined by the NanoString nCounter PanCancer immune Pathways Panel

  Immune gene panel - NanoString nCounter PanCancer immune panel                                    
  ---------------------------------------------------------------- ---------- ---------- ---------- -----------
  A2M                                                              C1R        CCND3      CD44       CLEC5A
  ABCB1                                                            C1S        CCR1       CD46       CLEC6A
  ABL1                                                             C2         CCR2       CD47       CLEC7A
  ADA                                                              C3         CCR3       CD48       CLU
  ADORA2A                                                          C3AR1      CCR4       CD5        CMA1
  AICDA                                                            C4BPA      CCR5       CD53       CMKLR1
  AIRE                                                             C5         CCR6       CD55       COL3A1
  AKT3                                                             C6         CCR7       CD58       COLEC12
  ALCAM                                                            C7         CCR9       CD59       CR1
  AMBP                                                             C8A        CCRL2      CD6        CR2
  AMICA1                                                           C8B        CD14       CD63       CREB1
  ANP32B                                                           C8G        CD160      CD68       CREB5
  ANXA1                                                            C9         CD163      CD7        CREBBP
  APOE                                                             CAMP       CD164      CD70       CRP
  APP                                                              CARD11     CD180      CD74       CSF1
  ARG1                                                             CARD9      CD19       CD79A      CSF1R
  ARG2                                                             CASP1      CD1A       CD79B      CSF2
  ATF1                                                             CASP10     CD1B       CD80       CSF2RB
  ATF2                                                             CASP3      CD1C       CD81       CSF3
  ATG10                                                            CASP8      CD1D       CD83       CSF3R
  ATG12                                                            CCL1       CD1E       CD84       CT45A1
  ATG16L1                                                          CCL11      CD2        CD86       CTAG1B
  ATG5                                                             CCL13      CD200      CD8A       CTAGE1
  ATG7                                                             CCL14      CD207      CD8B       CTCFL
  ATM                                                              CCL15      CD209      CD9        CTLA4
  AXL                                                              CCL16      CD22       CD96       CTSG
  BAGE                                                             CCL17      CD24       CD97       CTSH
  BATF                                                             CCL18      CD244      CD99       CTSL1
  BAX                                                              CCL19      CD247      CDH1       CTSS
  BCL10                                                            CCL2       CD27       CDH5       CTSW
  BCL2                                                             CCL20      CD274      CDK1       CX3CL1
  BCL2L1                                                           CCL21      CD276      CDKN1A     CX3CR1
  BCL6                                                             CCL22      CD28       CEACAM1    CXCL1
  BID                                                              CCL23      CD33       CEACAM6    CXCL10
  BIRC5                                                            CCL24      CD34       CEACAM8    CXCL11
  BLK                                                              CCL25      CD36       CEBPB      CXCL12
  BLNK                                                             CCL26      CD37       CFB        CXCL13
  BMI1                                                             CCL27      CD38       CFD        CXCL14
  BST1                                                             CCL28      CD3D       CFI        CXCL16
  BST2                                                             CCL3       CD3E       CFP        CXCL2
  BTK                                                              CCL3L1     CD3EAP     CHIT1      CXCL3
  BTLA                                                             CCL4       CD3G       CHUK       CXCL5
  C1QA                                                             CCL5       CD4        CKLF       CXCL6
  C1QB                                                             CCL7       CD40       CLEC4A     CXCL9
  C1QBP                                                            CCL8       CD40LG     CLEC4C     CXCR1
  CXCR2                                                            FOS        IFI27      IL19       IRAK4
  CXCR3                                                            FOXJ1      IFI35      IL1A       IRF1
  CXCR4                                                            FOXP3      IFIH1      IL1B       IRF2
  CXCR5                                                            FPR2       IFIT1      IL1R1      IRF3
  CXCR6                                                            FUT5       IFIT2      IL1R2      IRF4
  CYBB                                                             FUT7       IFITM1     IL1RAP     IRF5
  CYFIP2                                                           FYN        IFITM2     IL1RAPL2   IRF7
  CYLD                                                             GAGE1      IFNA1      IL1RL1     IRF8
  DDX43                                                            GATA3      IFNA17     IL1RL2     IRGM
  DDX58                                                            GNLY       IFNA2      IL1RN      ISG15
  DEFB1                                                            GPI        IFNA7      IL2        ISG20
  DMBT1                                                            GPR44      IFNA8      IL21       ITCH
  DOCK9                                                            GTF3C1     IFNAR1     IL21R      ITGA1
  DPP4                                                             GZMA       IFNAR2     IL22       ITGA2
  DUSP4                                                            GZMB       IFNB1      IL22RA1    ITGA2B
  DUSP6                                                            GZMH       IFNG       IL22RA2    ITGA4
  EBI3                                                             GZMK       IFNGR1     IL23A      ITGA5
  ECSIT                                                            GZMM       IGF1R      IL23R      ITGA6
  EGR1                                                             HAMP       IGF2R      IL24       ITGAE
  EGR2                                                             HAVCR2     IGLL1      IL25       ITGAL
  ELANE                                                            HCK        IKBKB      IL26       ITGAM
  ELK1                                                             HLA-A      IKBKE      IL27       ITGAX
  ENG                                                              HLA-B      IKBKG      IL28A      ITGB1
  ENTPD1                                                           HLA-C      IL10       IL29       ITGB2
  EOMES                                                            HLA-DMA    IL10RA     IL2RA      ITGB3
  EP300                                                            HLA-DMB    IL11       IL2RB      ITGB4
  EPCAM                                                            HLA-DOB    IL11RA     IL2RG      ITK
  ETS1                                                             HLA-DPA1   IL12A      IL3        JAK1
  EWSR1                                                            HLA-DPB1   IL12B      IL32       JAK2
  F12                                                              HLA-DQA1   IL12RB1    IL34       JAK3
  F13A1                                                            HLA-DQB1   IL12RB2    IL3RA      JAM3
  F2RL1                                                            HLA-DRA    IL13       IL4        KIR2DL1
  FADD                                                             HLA-E      IL13RA1    IL4R       KIR2DL3
  FAS                                                              HLA-G      IL13RA2    IL5        KIR3DL1
  FCER1A                                                           HMGB1      IL15       IL5RA      KIR3DL2
  FCER1G                                                           HRAS       IL15RA     IL6        KIR3DL3
  FCER2                                                            HSD11B1    IL16       IL6R       KIT
  FCGR1A                                                           ICAM1      IL17A      IL6ST      KLRB1
  FCGR2A                                                           ICAM2      IL17B      IL7        KLRC1
  FCGR2B                                                           ICAM3      IL17F      IL7R       KLRC2
  FCGR3A                                                           ICAM4      IL17RA     IL9        KLRD1
  FEZ1                                                             ICOS       IL17RB     ILF3       KLRF1
  FLT3                                                             ICOSLG     IL18       INPP5D     KLRG1
  FLT3LG                                                           IDO1       IL18R1     IRAK1      KLRK1
  FN1                                                              IFI16      IL18RAP    IRAK2      LAG3
  LAIR2                                                            MAPK3      NT5E       RELB       STAT2
  LAMP1                                                            MAPK8      NUP107     REPS1      STAT3
  LAMP2                                                            MAPKAPK2   OAS3       RIPK2      STAT4
  LAMP3                                                            MARCO      OSM        ROPN1      STAT5B
  LBP                                                              MASP1      PASD1      RORA       STAT6
  LCK                                                              MASP2      PAX5       RORC       SYCP1
  LCN2                                                             MAVS       PBK        RPS6       SYK
  LCP1                                                             MBL2       PDCD1      RRAD       SYT17
  LGALS3                                                           MCAM       PDCD1LG2   RUNX1      TAB1
  LIF                                                              MEF2C      PDGFC      RUNX3      TAL1
  LILRA1                                                           MEFV       PDGFRB     S100A12    TANK
  LILRA4                                                           MERTK      PECAM1     S100A7     TAP1
  LILRA5                                                           MFGE8      PIK3CD     S100A8     TAP2
  LILRB1                                                           MICA       PIK3CG     S100B      TAPBP
  LILRB2                                                           MICB       PIN1       SAA1       TARP
  LILRB3                                                           MIF        PLA2G1B    SBNO2      TBK1
  LRP1                                                             MME        PLA2G6     SELE       TBX21
  LRRN3                                                            MNX1       PLAU       SELL       TCF7
  LTA                                                              MPPED1     PLAUR      SELPLG     TFE3
  LTB                                                              MR1        PMCH       SEMG1      TFEB
  LTBR                                                             MRC1       PNMA1      SERPINB2   TFRC
  LTF                                                              MS4A1      POU2AF1    SERPING1   TGFB1
  LTK                                                              MS4A2      POU2F2     SH2B2      TGFB2
  LY86                                                             MSR1       PPARG      SH2D1A     THBD
  LY9                                                              MST1R      PPBP       SH2D1B     THBS1
  LY96                                                             MUC1       PRAME      SIGIRR     THY1
  LYN                                                              MX1        PRF1       SIGLEC1    TICAM1
  MAF                                                              MYD88      PRG2       SLAMF1     TICAM2
  MAGEA1                                                           NCAM1      PRKCD      SLAMF6     TIGIT
  MAGEA12                                                          NCF4       PRKCE      SLAMF7     TIRAP
  MAGEA3                                                           NCR1       PRM1       SLC11A1    TLR1
  MAGEA4                                                           NEFL       PSEN1      SMAD2      TLR10
  MAGEB2                                                           NFATC1     PSEN2      SMAD3      TLR2
  MAGEC1                                                           NFATC2     PSMB10     SMPD3      TLR3
  MAGEC2                                                           NFATC3     PSMB7      SOCS1      TLR4
  MAP2K1                                                           NFATC4     PSMB8      SPA17      TLR5
  MAP2K2                                                           NFKB1      PSMB9      SPACA3     TLR6
  MAP2K4                                                           NFKB2      PSMD7      SPINK5     TLR7
  MAP3K1                                                           NFKBIA     PTGS2      SPN        TLR8
  MAP3K5                                                           NLRC5      PTPRC      SPO11      TLR9
  MAP3K7                                                           NLRP3      PVR        SPP1       TMEFF2
  MAP4K2                                                           NOD1       PYCARD     SSX1       TNF
  MAPK1                                                            NOD2       RAG1       SSX4       TNFAIP3
  MAPK11                                                           NOTCH1     REL        ST6GAL1    TNFRSF10B
  MAPK14                                                           NRP1       RELA       STAT1      TNFRSF10C
  TNFRSF11A                                                        TNFRSF4    TNFSF18    TREM1      VEGFA
  TNFRSF11B                                                        TNFRSF8    TNFSF4     TREM2      VEGFC
  TNFRSF12A                                                        TNFRSF9    TNFSF8     TTK        XCL2
  TNFRSF13B                                                        TNFSF10    TOLLIP     TXK        XCR1
  TNFRSF13C                                                        TNFSF11    TP53       TXNIP      YTHDF2
  TNFRSF14                                                         TNFSF12    TPSAB1     TYK2       ZAP70
  TNFRSF17                                                         TNFSF13    TPTE       UBC        ZNF205
  TNFRSF18                                                         TNFSF13B   TRAF2      ULBP2      
  TNFRSF1A                                                         TNFSF14    TRAF3      USP9Y      
  TNFRSF1B                                                         TNFSF15    TRAF6      VCAM1      

  Immune gene panel -- IFN-γ associated genes                                   
  --------------------------------------------- ---------- --------- ---------- ----------
  ADAR                                          CSF2RB     IFI44     LGALS3BP   PNP
  APOL6                                         CXCL10     IFI44L    LY6E       PNPT1
  ARID5B                                        CXCL11     IFIH1     LYSMD2     PRIC285
  ARL4A                                         CXCL9      IFIT1     MAR-01     PSMA2
  AUTS2                                         DDX58      IFIT2     METTL7B    PSMA3
  B2M                                           DDX60      IFIT3     MT2A       PSMB10
  BANK1                                         DHX58      IFITM2    MTHFD2     PSMB2
  BATF2                                         EIF2AK2    IFITM3    MVP        PSMB8
  BPGM                                          EIF4E3     IFNAR2    MX1        PSMB9
  BST2                                          EPSTI1     IL10RA    MX2        PSME1
  BTG1                                          FAS        IL15      MYD88      PSME2
  C1R                                           FCGR1A     IL15RA    NAMPT      PTGS2
  C1S                                           FGL2       IL18BP    NCOA3      PTPN1
  CASP1                                         FPR1       IL2RB     NFKB1      PTPN2
  CASP3                                         FTSJD2     IL4R      NFKBIA     PTPN6
  CASP4                                         GBP4       IL6       NLRC5      RAPGEF6
  CASP7                                         GBP6       IL7       NMI        RBCK1
  CASP8                                         GCH1       IRF1      NOD1       RIPK1
  CCL2                                          GPR18      IRF2      NUP93      RIPK2
  CCL5                                          GZMA       IRF4      OAS2       RNF213
  CCL7                                          HERC6      IRF5      OAS3       RNF31
  CD274                                         HIF1A      IRF7      OASL       RSAD2
  CD38                                          HLA-A      IRF8      OGFR       RTP4
  CD40                                          HLA-B      IRF9      P2RY14     SAMD9L
  CD69                                          HLA-DMA    ISG15     PARP12     SAMHD1
  CD74                                          HLA-DQA1   ISG20     PARP14     SECTM1
  CD86                                          HLA-DRB1   ISOC1     PDE4B      SELP
  CDKN1A                                        HLA-G      ITGB7     PELI1      SERPING1
  CFB                                           ICAM1      JAK2      PFKP       SLAMF7
  CFH                                           IDO1       KLRK1     PIM1       SLC25A28
  CIITA                                         IFI27      LAP3      PLA2G4A    SOCS1
  CMKLR1                                        IFI30      LATS2     PLSCR1     SOCS3
  CMPK2                                         IFI35      LCP2      PML        SOD2
  SP110                                         STAT2      TNFAIP3   TRIM25     VAMP8
  SPPL2A                                        STAT3      TNFAIP6   TRIM26     VCAM1
  SRI                                           STAT4      TNFSF10   TXNIP      WARS
  SSPN                                          TAP1       TOR1B     UBE2L6     XAF1
  ST3GAL5                                       TAPBP      TRAFD1    UPP1       XCL1
  ST8SIA4                                       TDRD7      TRIM14    USP18      ZBP1
  STAT1                                         TNFAIP2    TRIM21    VAMP5      ZNFX1

  Immune gene panel -- IFN-α associated genes                                  
  --------------------------------------------- --------- ---------- --------- ----------
  ADAR                                          FAM125A   IL4R       OGFR      SLC25A28
  B2M                                           FAM46A    IL7        PARP12    SP110
  BATF2                                         FTSJD2    IRF1       PARP14    STAT2
  BST2                                          GBP2      IRF2       PARP9     TAP1
  C1S                                           GBP4      IRF7       PLSCR1    TDRD7
  CASP1                                         GMPR      IRF9       PNPT1     TMEM140
  CASP8                                         HERC6     ISG15      PRIC285   TRAFD1
  CCRL2                                         HLA-C     ISG20      PROCR     TRIM14
  CD47                                          IFI27     LAMP3      PSMA3     TRIM21
  CD74                                          IFI30     LAP3       PSMB8     TRIM25
  CMPK2                                         IFI35     LGALS3BP   PSMB9     TRIM26
  CNP                                           IFI44     LPAR6      PSME1     TRIM5
  CSF1                                          IFI44L    LY6E       PSME2     TXNIP
  CXCL10                                        IFIH1     MOV10      RIPK2     UBA7
  CXCL11                                        IFIT2     MX1        RNF31     UBE2L6
  DDX60                                         IFIT3     NCOA7      RSAD2     USP18
  DHX58                                         IFITM1    NMI        RTP4      WARS
  EIF2AK2                                       IFITM2    NUB1       SAMD9     
  ELF1                                          IFITM3    OAS1       SAMD9L    
  EPSTI1                                        IL15      OASL       SELL      

  Immune gene panel -- cytotoxic associated genes                               
  ------------------------------------------------- --------- -------- -------- ----------
  ABCB1                                             CCL8      CTLA4    FFAR3    HERC6
  ADAM19                                            CCR5      CXCL10   FUT2     HESX1
  ADAM3A                                            CD163L1   CXCL11   GAS6     HS3ST3B1
  ADORA3                                            CD28      CXCL9    GBP6     IDO1
  ANKRD22                                           CD300E    DNA2     GIMAP4   IFNB1
  APOL3                                             CD38      DPCD     GIMAP5   IFNG
  ARNT2                                             CD5       ENPP2    GIMAP7   IL10
  ATF5                                              CD8A      F13A1    GIMAP8   IL12RB2
  BATF2                                             CDC7      F2R      GNLY     IL15
  BCL2                                              CDK6      FAM20A   GPR171   IL15RA
  BCL2L14                                           CH25H     FAM26F   GZMB     IL21
  C5orf39                                           CMKLR1    FAM40B   GZMK     IL2RA
  CASC5                                             CMPK2     FBXO39   HAMP     IL4I1
  CCL7                                              CRABP1    FCGR2B   HAPLN3   IRF4
  ISG15                                             MYBL1     PRKCQ    SDS      TMEM229B
  ITGA9                                             NKG7      PTGER2   SH2D1A   TNFSF18
  KIAA1199                                          OR2A5     RGL1     SLA2     TRAT1
  KLHDC1                                            OR5D14    RHBDF2   SLAMF1   TSHZ3
  KLRD1                                             OR6K6     RNASE2   SMOX     TXK
  LILRB5                                            P2RX5     RRM2     SOCS1    TYMS
  MERTK                                             PLEKHO1   RTP4     SSTR2    USP18
  MKI67                                             PRF1      RUNX3    STAB1    
  MS4A6E                                            PRKCA     SAMD3    STAT4    

###### Gene Ontology classes enriched in the overall 377 genes (a) and 157 top ranked genes (b) GO categories defined by PANTHER pathway tool \[[@R27], [@R33]\]

  Analysis Type:                                                               PANTHER Overrepresentation Test (release 20160715)                                                                                                
  ---------------------------------------------------------------------------- ---------------------------------------------------- ---------------- --------------------- ----------------------- ----------------------------- --------------------
  **Annotation Version and Release Date:**                                     **PANTHER version 11.1 Released 2016-10-24**                                                                                                      
  **Analyzed List:**                                                           **377genes (Homo sapiens)**                                                                                                                       
  **Reference List:**                                                          **Homo sapiens (all genes in database)**                                                                                                          
  **Bonferroni correction:**                                                   **TRUE**                                                                                                                                          
  **Bonferroni count:**                                                        **158**                                                                                                                                           
  PANTHER Pathways                                                             Homo sapiens - REFLIST (20972)                       377genes (385)   377genes (expected)   377genes (over/under)   377 genes (fold Enrichment)   377genes (P-value)
  JAK/STAT signaling pathway (P00038)                                          17                                                   6                0.31                  \+                      19.23                         1.50E-04
  Toll receptor signaling pathway (P00054)                                     60                                                   21               1.1                   \+                      19.07                         5.00E-18
  Interleukin signaling pathway (P00036)                                       98                                                   23               1.8                   \+                      12.78                         4.53E-16
  T cell activation (P00053)                                                   96                                                   22               1.76                  \+                      12.48                         4.03E-15
  B cell activation (P00010)                                                   72                                                   15               1.32                  \+                      11.35                         1.83E-09
  p38 MAPK pathway (P05918)                                                    42                                                   7                0.77                  \+                      9.08                          2.49E-03
  Apoptosis signaling pathway (P00006)                                         122                                                  20               2.24                  \+                      8.93                          5.24E-11
  Inflammation mediated by chemokine and cytokine signaling pathway (P00031)   261                                                  36               4.79                  \+                      7.51                          3.53E-18
  Blood coagulation (P00011)                                                   47                                                   6                0.86                  \+                      6.95                          4.23E-02
  VEGF signaling pathway (P00056)                                              72                                                   8                1.32                  \+                      6.05                          1.08E-02
  Ras Pathway (P04393)                                                         76                                                   8                1.4                   \+                      5.73                          1.56E-02
  CCKR signaling map (P06959)                                                  173                                                  17               3.18                  \+                      5.35                          6.02E-06
  p53 pathway (P00059)                                                         88                                                   8                1.62                  \+                      4.95                          4.19E-02
  Angiogenesis (P00005)                                                        176                                                  16               3.23                  \+                      4.95                          4.23E-05
  Integrin signalling pathway (P00034)                                         192                                                  17               3.52                  \+                      4.82                          2.59E-05
  EGF receptor signaling pathway (P00018)                                      139                                                  11               2.55                  \+                      4.31                          1.07E-02
  Gonadotropin-releasing hormone receptor pathway (P06664)                     235                                                  15               4.31                  \+                      3.48                          6.36E-03
  Unclassified (UNCLASSIFIED)                                                  18333                                                232              336.55                \-                      0.69                          0.00E+00

  Analysis Type:                                                               PANTHER Overrepresentation Test (release 20160715)                                                                                                                           
  ---------------------------------------------------------------------------- ---------------------------------------------------- ----------------------- ---------------------------- ------------------------------ ----------------------------------- ---------------------------
  **Annotation Version and Release Date:**                                     **PANTHER version 11.1 Released 2016-10-24**                                                                                                                                 
  **Analyzed List:**                                                           **157 genes (Homo sapiens)**                                                                                                                                                 
  **Reference List:**                                                          **Homo sapiens (all genes in database)**                                                                                                                                     
  **Bonferroni correction:**                                                   **TRUE**                                                                                                                                                                     
  **Bonferroni count:**                                                        **158**                                                                                                                                                                      
  PANTHER Pathways                                                             Homo sapiens - REFLIST (20972)                       157 genes Input (158)   157 genes Input (expected)   157 genes Input (over/under)   157 genes Input (fold Enrichment)   157 genes Input (P-value)
  JAK/STAT signaling pathway (P00038)                                          17                                                   3                       0.13                         \+                             23.42                               4.94E-02
  Interleukin signaling pathway (P00036)                                       98                                                   9                       0.74                         \+                             12.19                               1.20E-05
  B cell activation (P00010)                                                   72                                                   6                       0.54                         \+                             11.06                               3.25E-03
  Toll receptor signaling pathway (P00054)                                     60                                                   5                       0.45                         \+                             11.06                               1.62E-02
  T cell activation (P00053)                                                   96                                                   7                       0.72                         \+                             9.68                                1.55E-03
  Inflammation mediated by chemokine and cytokine signaling pathway (P00031)   261                                                  12                      1.97                         \+                             6.1                                 1.34E-04
  Integrin signalling pathway (P00034)                                         192                                                  8                       1.45                         \+                             5.53                                1.86E-02
  Unclassified (UNCLASSIFIED)                                                  18333                                                96                      138.12                       \-                             0.7                                 0.00E+00

![Bar graph depicting distribution of fold enrichment levels of biological pathways defined by PANTHER based analysis in the 377 genes that show differential expression patterns in the four TCGA MIBC clusters\
The enriched categories were obtained upon analysis using the statistical overrepresentation test defined by PANTHER tool \[[@R27]\].](oncotarget-08-70982-g007){#F7}

DISCUSSION {#s3}
==========

Evolving research from correlative studies as well as clinical trials, including those for UBC, have emphasized the value of the pre-existing tumour immune state as a predictor of response to treatment and survival \[[@R29], [@R30]\]. Furthermore, UBC is associated with a comparatively high mutational burden \[[@R31]\], which could potentially contribute to increased immunogenicity making them more susceptible to novel immunotherapy-based approaches. In order to gain a better understanding of the pre-existing tumour immune landscape in UBC, we conducted a comprehensive *in silico* immune transcriptomic profiling of the MIBC tumours from the TCGA database.

Four distinct molecular subtypes in MIBC were defined recently based on the TCGA MIBC genome wide profiling datasets \[[@R6]\]. Indeed, variability in subtype nomenclature has been reported \[[@R10]\], which could be attributed to heterogeneity in tissue samples in addition to several other factors such as inclusion of NMIBC cases in classification schemes. However, since the TCGA bladder cohort is enriched for MIBC and gene expression based clusters have been well defined, we specifically used this cohort to address our question on immune gene expression patterns associated with genomic alterations. Based on the distinct immune signature between clusters in cohort 1 (n=122), we were able to assign cohort 2 (n=225) into the associated TCGA clusters using the top 20% of ranked immune genes from the training cohort. Further analysis on the IFN-γ, IFN-α, and cytotoxic genes were then compared in both cohorts. All of these analyses revealed an increased expression of immune-associated genes in Cluster IV and underactive immune environment in Cluster I. Given that specific genetic alterations associate with these molecular subtypes, it seems that anti-tumour immune responses could be partly driven by oncogenic drivers.

Cluster I has been previously reported to show higher expression of *FGFR3* via mutations, amplifications, and other mechanisms \[[@R3]\]. Interestingly this cluster showed a distinct underactive tumour immune state with reduced expression of IFN genes and genes associated with T-helper type-1 response. It is indeed intriguing that tumours with *FGFR3* mutations or overexpression as per previous classification \[[@R6]\], show an increased overall survival, which contradicts the underactive immune state observed here. In contrast, cases in cluster IV showed the most dominant immune response amongst all four clusters. Tumours in this cluster show decreased expression of *PPAR-γ* and *GATA3*, and significantly increased expression of IFN and antigen presentation pathway genes, in addition to MHC class II genes and those involved in T-cell cytolytic activity. Previous reports have shown that based on broader classifications, cases in cluster IV belong to the basal subtype, which shows poor overall survival \[[@R8]\], \[[@R9]\]. One potential contributor to these associations is the increased expression of immune checkpoint molecules such as *CD274 (PD-L1)*, *IDO1* and the immunosuppressive *IL6* in clusters III and IV that potentially lead to increased resistance to cytotoxic killing and poor response to treatment and ultimately poor survival. As previously shown, this cluster also shows higher levels of EMT related genes, indicating more aggressive tumour phenotype \[[@R33]\]. Our recent report demonstrating that higher PD-L1 expression in cancer cells leads to increased drug resistance upon activation by IFN-γ or PD-1 \[[@R32]\] supports this notion. It could thus be speculated that the IFN-γ secreted by activated T-cells, reflected by the increased expression of *GZMA* in these clusters, could be inducing PD-L1 on the cancer cells with further interaction between these leading to T-cell dysfunction. However, the mechanistic basis of these significant associations needs to be explored further. In other cancers such as melanoma, colorectal, and ovarian, higher expression of IFN pathway genes and of those representing an active immune response is associated with a favourable treatment outcome and overall survival. Furthermore, it is also possible that factors other than anti-tumour immune responses contribute to increased survival rates in tumours with *FGFR3* mutations in MIBC.

Increased expression of MHC class II genes *CD74, HLA-DMB,* and *HLA-DQA1* indicate higher tumour antigen processing by the antigen presenting cells in clusters III and IV. This was also confirmed by gene ontology-based analysis, which reflected a dominance of response to IFN-γ, antigen processing and presentation, cytokine mediated signaling, and cell proliferation, NK cell and macrophage activation, and B cell mediated immunity. These enrichments not only confirm the increased active anti-tumour immune response in clusters IV and some of cluster III but also indicate the immunogenic nature of these clusters that could be potentially be driven by higher mutational burden and recognition of immune cells.

Overall, our findings based on comprehensive immune transcriptomic analysis have significant implications in informing treatment decisions based on immune gene expression patterns. Specifically, since immune checkpoint blockade therapy has shown some promise in bladder cancer \[[@R15]\], near future biomarker driven clinical trials will benefit from these findings that emphasize appropriate patient stratification for treatment. Although recent reports have described the presence of T-cell inflamed and non-inflamed MIBC tumours \[[@R17], [@R33]\], no previous reports have identified associations between immune response and IFN-associated genes with the four molecular MIBC subtypes. Our study is limited by the fact that the TCGA dataset is enriched for MIBC and thus further validations in other cohorts need to be performed; however, these associations are timely and complement the ongoing and future clinical trials based on immune-based therapies. Clinical translation of our findings will most appropriately be addressed by validation of the most significant differentially expressed genes at both transcriptional and proteomic levels in retrospective and prospective pre-treatment bladder tumour specimens. Future investigations by integration of genomic alterations determined by exome and transcriptome sequencing data are key to identifying the genomic determinants of variability in immune response. Finally our study provides an improved understanding of the bladder cancer molecular subtype associated immune gene expression patterns and will significantly impact the design of novel immune based therapies.

MATERIALS AND METHODS {#s4}
=====================

Patient tumour samples {#s4_1}
----------------------

The publicly available global transcriptomic sequencing (RNA-Seq) data from 412 MIBC cases, with the corresponding clinical information was downloaded from TCGA data portal (<https://gdc-portal.nci.nih.gov/>), now part of the National Cancer Institute's Genetic Data Commons. The cohort was further divided into two cohorts for downstream analysis. For our training cohort (cohort 1) we used data from the previously defined 129 cases from TCGA that were divided into four clusters based on their integrated analysis of mRNA, miRNA, and protein data \[[@R6]\]. Since our objective was to define immune gene expression patterns in treatment naïve tumours, we excluded patients with any previous therapy. Thus a cohort of 122 MIBC cases, divided into four molecular clusters, was used for *in silico* immune profiling. The remaining 283 cases constituted the validation cohort (cohort 2) of which 225 had no prior therapy.

Design of immune pathway gene panel for *in silico* immune profiling {#s4_2}
--------------------------------------------------------------------

To investigate the presence of subtype associated immune signatures, we assembled a defined set of 924 immune related genes. This curated list (Table [1](#T1){ref-type="table"}) primarily consisted of genes involved in IFN-α (97 genes), IFN-γ (200 genes), and cytotoxic (115 genes) pathways as defined by Gene Set Enrichment Analysis (GSEA) in combination with other immune genes. The nCounter PanCancer Immune profiling panel (722 genes), (<http://www.nanostring.com/products/pancancer_immune/>) was used to derive the immune response related genes.

Bioinformatics analysis of RNA-Seq data {#s4_3}
---------------------------------------

We used the upper quartile-normalized RNA-seq data by expectation maximization (RSEM) available for all selected cases at the TCGA data portal. No additional normalization was performed and the expression data were log~2~ transformed. All downstream data analysis was performed in MATLAB (Mathworks, Inc., Natick, Massachusetts, USA). Focusing on the first set of 122 samples, where clustering information is known, we performed separate analyses of the genes in each of the four immune panels (NanoString™, IFN-α, IFN-γ, and T cell cytotoxicity associated genes). Using a feature selection algorithm, genes were ranked based on their ability to discriminate samples belonging to one cluster from the remaining. The feature selection algorithm uses an ensemble of five different machine-learning techniques (unpublished). The analysis resulted in 16 ranking tables, four tables for each immune panel, where each table ranked genes on their ability to discriminate samples in one cluster from the rest.

In the hierarchical clustering analysis, the top 20% of genes in each ranking group were assembled to represent each immune panel, resulting in 377 genes (Nanostring), 44 genes (IFN-α), 91 genes (IFN-γ), and 62 genes (T cell cytotoxicity). A final feature selection ranking was performed where the combined unique set of 924 genes was used. The top 5% of genes in each of the four ranking groups were then merged, resulting in 157 unique genes.

Gene ontology analysis using PANTHER {#s4_4}
------------------------------------

We used the Protein Analysis Through Evolutionary Relationships (PANTHER), version 11.0, classification system (<http://www.pantherdb.org/>) \[[@R27]\] to determine dominant and enriched pathways in the top ranking 377 genes (NanoString panel) that were ranked based on their ability to discriminate samples across the four clusters. We then applied the statistical binomial overrepresentation test, as previously described in PANTHER \[[@R27]\], to derive the most dominant enriched pathways and gene ontology (GO) biological processes in our lists compared to the reference human genome. We performed these tests using both the 377 top ranking NanoString™ genes and 157 top ranked genes from all immune panels combined. The p-values were corrected for multiple testing using Bonferroni correction.

Validation of immune gene signature {#s4_5}
-----------------------------------

The remaining 298 cases, not included in cohort 1, were treated as a validation group. From this cohort, patients with previous BCG therapy were excluded, leaving 225 cases. In order to assign samples in this set to each of the four clusters, only the top ranked 377 genes from the NanoString panel were used. First, for each cluster, two cluster centroids were computed using the expression data from cohort 1 (n=122; total of 8 cluster centroids). The cluster centroids were computed by taking the mean expression of samples in a given cluster (main cluster) and the mean expression of samples that do not belong to that cluster (alternative cluster). Then, for each sample in cohort 2, the Euclidean distance was computed to each of the 8 cluster centroids. A sample was assigned to a cluster with the smallest distance to the main cluster, but only if the distance to the main cluster was smaller than the distance to the alternative cluster. Alternatively, the sample was assigned to the 'unclassified' cluster. Using the newly assigned clustering information and ranked list of genes, unsupervised hierarchical clustering was performed.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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